GlucoTrack Financial Statements From 2010 to 2025

GCTK Stock  USD 5.15  0.58  10.12%   
Analyzing historical trends in various income statement and balance sheet accounts from GlucoTrack's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting GlucoTrack's valuation are summarized below:
Gross Profit
-20 K
Market Capitalization
5.2 M
Earnings Share
-1.3 K
There are currently one hundred twenty fundamental trends for GlucoTrack that can be evaluated and compared over time across competitors. We recommend to confirm GlucoTrack's regular fundamental drivers against the all of the trends between 2010 and 2025.

GlucoTrack Total Revenue

0.0

Check GlucoTrack financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GlucoTrack's main balance sheet or income statement drivers, such as Depreciation And Amortization of 37.8 K, Interest Expense of 650 K or Selling General Administrative of 2.4 M, as well as many indicators such as Price To Sales Ratio of 21.3 K, Dividend Yield of 0.0 or Days Sales Outstanding of 84.39. GlucoTrack financial statements analysis is a perfect complement when working with GlucoTrack Valuation or Volatility modules.
  
Build AI portfolio with GlucoTrack Stock
Check out the analysis of GlucoTrack Correlation against competitors.
For more information on how to buy GlucoTrack Stock please use our How to buy in GlucoTrack Stock guide.

GlucoTrack Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding232.9 K371.9 K286.3 K
Very volatile
Total AssetsM5.9 M3.5 M
Slightly volatile
Short and Long Term Debt Total244.4 K267 K320.5 K
Slightly volatile
Other Current Liabilities239.4 K252 K481.8 K
Very volatile
Total Current Liabilities1.7 M1.3 M1.4 M
Slightly volatile
Property Plant And Equipment Net171 K154 K151.9 K
Pretty Stable
Accounts PayableM992 K886.7 K
Slightly volatile
Cash3.2 M5.6 M2.8 M
Slightly volatile
Non Current Assets Total218 K164 K264.1 K
Pretty Stable
Non Currrent Assets Other8.6 KK98.7 K
Slightly volatile
Cash And Short Term Investments3.2 M5.6 M2.8 M
Slightly volatile
Liabilities And Stockholders EquityM5.9 M3.5 M
Slightly volatile
Non Current Liabilities Total18.5 M17.7 M6.1 M
Pretty Stable
Other Current Assets146.3 K151 K131.3 K
Pretty Stable
Other Stockholder Equity72.2 M119.5 M62.8 M
Slightly volatile
Total Liabilities19.9 M18.9 M7.5 M
Pretty Stable
Total Current Assets3.7 M5.8 M3.3 M
Slightly volatile
Common Stock950100026 K
Pretty Stable
Short Term Debt26.5 K27.9 K122.2 K
Slightly volatile
Other Liabilities146.8 K154.5 K560.1 K
Slightly volatile
Property Plant Equipment34.2 K36 K173.7 K
Slightly volatile
Long Term Debt213.7 K203 K182.4 K
Slightly volatile
Capital Stock9501000105.7 K
Slightly volatile
Property Plant And Equipment Gross146.3 K154 K665.7 K
Slightly volatile
Short and Long Term DebtK4.5 K4.9 K
Slightly volatile

GlucoTrack Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative2.4 M4.7 M2.4 M
Slightly volatile
Other Operating Expenses15.3 M14.5 M5.9 M
Slightly volatile
Research Development10 M9.5 M3.2 M
Slightly volatile
Cost Of Revenue41.9 K36 K45.2 K
Pretty Stable
Selling And Marketing Expenses215 K393 K161 K
Slightly volatile
Reconciled Depreciation32.3 K36 K49.1 K
Slightly volatile
Interest Income32.6 K62 K76 K
Slightly volatile

GlucoTrack Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation164.3 K173 K459.8 K
Pretty Stable
Begin Period Cash Flow2.7 M4.5 M2.4 M
Slightly volatile
Depreciation42.4 K36 K38.8 K
Pretty Stable
End Period Cash Flow3.1 M5.6 M2.8 M
Slightly volatile
Change To Netincome616.2 K449.1 K1.4 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio21.3 K24 K26.2 K
Slightly volatile
Dividend Yield0.00.00.0
Slightly volatile
Days Sales Outstanding84.39110118
Pretty Stable
Average Payables1.2 M1.6 M1.4 M
Slightly volatile
Stock Based Compensation To Revenue3.252.212.6871
Pretty Stable
Capex To Depreciation3.493.321.4576
Pretty Stable
Inventory Turnover0.320.190.3871
Slightly volatile
Days Of Inventory On Hand3.5 K2.5 K2.3 K
Pretty Stable
Payables Turnover0.03450.03630.1464
Slightly volatile
Sales General And Administrative To Revenue8.348.7820.0728
Slightly volatile
Average Inventory582.5 K507.8 K506.8 K
Slightly volatile
Research And Ddevelopement To Revenue6.586.9218.9005
Slightly volatile
Capex To Revenue0.120.130.4628
Slightly volatile
Cash Per Share14.3515.103197.9541
Slightly volatile
Days Payables Outstanding9.6 K10.1 K183.3 K
Slightly volatile
Current Ratio3.914.52393.7939
Pretty Stable
Receivables Turnover4.93.433.5782
Very volatile
Capex Per Share0.310.321.956
Slightly volatile
Average Receivables77.2 K53.3 K58 K
Very volatile
Revenue Per Share1.41.581.7213
Slightly volatile
Interest Debt Per Share2.172.28559.3931
Slightly volatile
Debt To Assets0.04280.0450.1263
Slightly volatile
Operating Cycle3.6 K2.5 K2.4 K
Pretty Stable
Days Of Payables Outstanding9.6 K10.1 K183.3 K
Slightly volatile
Operating Profit Margin14.3615.1139.0772
Slightly volatile
Ebit Per Revenue14.3615.1139.0772
Slightly volatile
Quick Ratio3.764.52393.67
Pretty Stable
Net Income Per E B T0.790.90.979
Slightly volatile
Cash Ratio3.614.40553.5139
Pretty Stable
Days Of Inventory Outstanding3.5 K2.5 K2.3 K
Pretty Stable
Days Of Sales Outstanding84.39110118
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.111.161.0269
Slightly volatile
Fixed Asset Turnover1.340.750.874
Pretty Stable
Debt Ratio0.04280.0450.1263
Slightly volatile
Price Sales Ratio21.3 K24 K26.2 K
Slightly volatile
Asset Turnover0.120.150.1164
Slightly volatile

GlucoTrack Fundamental Market Drivers

GlucoTrack Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About GlucoTrack Financial Statements

GlucoTrack investors utilize fundamental indicators, such as revenue or net income, to predict how GlucoTrack Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Cost Of Revenue36 K41.9 K
Stock Based Compensation To Revenue 2.21  3.25 
Sales General And Administrative To Revenue 8.78  8.34 
Research And Ddevelopement To Revenue 6.92  6.58 
Capex To Revenue 0.13  0.12 
Revenue Per Share 1.58  1.40 
Ebit Per Revenue 15.11  14.36 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether GlucoTrack is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlucoTrack Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glucotrack Stock. Highlighted below are key reports to facilitate an investment decision about Glucotrack Stock:
Check out the analysis of GlucoTrack Correlation against competitors.
For more information on how to buy GlucoTrack Stock please use our How to buy in GlucoTrack Stock guide.
You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlucoTrack. If investors know GlucoTrack will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlucoTrack listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
-1.3 K
Return On Assets
(2.26)
Return On Equity
(14.91)
The market value of GlucoTrack is measured differently than its book value, which is the value of GlucoTrack that is recorded on the company's balance sheet. Investors also form their own opinion of GlucoTrack's value that differs from its market value or its book value, called intrinsic value, which is GlucoTrack's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlucoTrack's market value can be influenced by many factors that don't directly affect GlucoTrack's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlucoTrack's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlucoTrack is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlucoTrack's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.